This trial evaluates a specific type of radiation therapy for advanced prostate cancer. The main outcome to be measured is whether or not the therapy will damage the surrounding organs. This trial is taking place in Pennsylvania, USA.
Prostate cancer is an uncontrolled growth of the cells which make up the prostate gland. Prostate cancer can be treated by medication, surgery or radiation. Radiation therapy uses radio waves to kill the cancerous prostate tissue. Radiation therapy can be delivered in a variety of ways. It can be delivered from outside the body or inside the body, at the cancer site. CyberKnife stereotactic body radiation therapy is a type of radiation therapy delivered from outside the body. It is delivered from different positions and the beams meet at the tumor site.
This trial aims to evaluate if higher doses of CyberKnife radiation therapy can target prostate cancer in the prostate and the surrounding areas. The main outcomes to be measured are side effects to the urinary or genital systems and effectiveness.
Who are they looking for?
100 patients are needed for this study. Patients must have high-risk prostate carcinoma. Patients must have a prostate volume lower than 100 ccs.
Patients cannot have had recent (in the last 5 years) or current other cancers, other than non-melanoma skin cancers. Patients cannot have any psychiatric or medical illnesses which may interfere with the trial visits. Patients cannot have implanted devices around the prostate which may interfere with treatment. Patients cannot have a contraindication to hormone therapy before.
How will it work
All patients will receive CyberKnife radiation. They will be followed up for side effects to the urinary and genital functions up to 24 months. Survival without cancer and overall survival will also be evaluated up to 5 years.